International: +1-347-960-6455
Major Depressive Disorder Therapeutics - Pipeline Analysis 2018

Major Depressive Disorder Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10105 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Neurology
Select License Type

Major depressive disorder, also known as the clinical depression, is characterized by a constant sense of despair and hopelessness. It usually affects daily activities such as study, sleep, and eating. Common symptoms observed in major depressive disorder are fatigue, indecisiveness, impaired concentration, feelings of worthlessness or guilt, insomnia or hypersomnia, restlessness, significant weight loss or gain and recurring thoughts of death or suicide. According to the National Institute of Mental Health, an estimated 16.1 million adults aged 18 or older in the U.S. had at least one major depressive episode in 2014.

VistaGen Therapeutics Inc. is developing AV-101, a new generation oral antidepressant, for the treatment of major depressive disorder. NeurOp Inc., and ACADIA Pharmaceuticals Inc. are some other key players involved in the development of drugs for the treatment of major depressive disorder.  

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.